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LETTERS TO THE EDITORResponse to Sandford et al.:
PRICKLE2 Variants in Epilepsy:
A Call for Precision MedicineTo the Editor: With the arrival of massively parallel
sequencing (MPS), we now face the situation where we
often discover several rare mutations in a single individual.
So, how do we know which genes are associated with
which phenotypes? Although this issue is common in
2016, it was not always the case. In the not-so-distant
past, gene sequencing itself was a laborious process, and
many genetic studies necessarily took a candidate-gene
approach. The letter from Sandford et al. struggles with
this recent history.1
Sandford et al. write that two siblings with epilepsy
and a variant in PRICKLE2 (MIM: 608501), reported by
Tao et. al.,2 also harbor POLG (MIM: 174763) mutations—
an important clinical result for this family. As they point
out, POLGmutations were known to be involved with epi-
lepsy and ataxia as early as 2001— some 10 years before our
report,2 which Dr. Bird also co-authored. They also note
that the sibling relationship was described by Bird and
Shaw in 1978.3 So, given that Dr. Bird had the DNA since
1978 and that POLG mutations were described in 2001,
why was DNA submitted for PRICKLE2 variant analysis
with us in 2011, and why is he reporting on POLG muta-
tions in 2016? The answer, in part, is that genotyping indi-
viduals was not always as easy as it is today.
The answer could also be that PRICKLE2 variants might
indeed be part of this family’s phenotype. Certainly, most
of the family’s phenotype (e.g., the brain malformation)
corresponds to that of other individuals with POLG muta-
tions, but seizures and the degree of seizure severity are
variable among those with POLG mutations. Could the
PRICKLE2 variants in these two siblings contribute to the
seizure phenotype?
Recently, results by others have strongly suggested
that PRICKLE2 variants are associated with epilepsy.
For example, a recent report described whole-exome
sequencing in an individual with epilepsy, intellectual
disability, and anxiety; this person harbors a de novo
frameshift variant (c.380delG [p.Glu127fs*46] [GenBank:
NM_198859.3], not found in the Exome Aggregation Con-
sortium [ExAC] Browser) in PRICKLE2.4,5 Interestingly, this
individual also has one other de novo variant—a single-
nucleotide variant (c.5614A>G [p.Met1872Val] [GenBank:
NM_004380.2]) in CREBBP (MIM: 600140)—and children
with CREBBP mutations have been reported to have
Rubinstein-Taybi syndrome 1 (MIM 180849), although
this individual was not reported to have Rubinstein-Taybi
syndrome 1. Moreover, some but not all individuals with
CREBBP mutations have epilepsy. So, is the de novo590 The American Journal of Human Genetics 98, 590–591, March 3PRICKLE2 frameshift mutation the sole cause of this indi-
vidual’s epilepsy, is the CREBBP mutation involved, or
does the combination of the two lead to the condition?
We cannot answer these questions with DNA sequencing
alone.
Similarly, we recently described a de novo mutation (not
in the ExAC Browser) in the closely related gene PRICKLE1
(MIM: 608500) in a fetus with polymicrogyria (comorbid
with epilepsy inmost affected individuals).6 The previously
reported epileptic individuals with PRICKLE1 variants had
inherited their PRICKLE1 alleles and did not have polymi-
crogyria.7 This de novo mutation represents a more severe
case than those previously described. In retrospect, were
some individuals mistakenly diagnosed with other disor-
ders when their brain malformations and/or epilepsy
were in fact caused by PRICKLE1 and/or PRICKLE2 muta-
tions? This will most likely be answered in the near future,
as clinical MPS data become widely available.
Sandford et al. state, ‘‘Other papers have confirmed that
large heterozygous deletions, including PRICKLE2, on
chromosome 3 are associated with autism, but nothing
about epilepsy was mentioned in this or other publica-
tions.’’ This is simply false. As early as 1981, in a child
with an interstitial deletion that would encompass
PRICKLE2 (although banding was low resolution at that
date) ‘‘grand mal seizures appeared at 6 months of age
but were successfully treated.’’8 Even more definitively, in
1997 a publication described a de novo interstitial deletion
that encompassed PRICKLE2 in a baby in whom ‘‘seizures
started on the first day of life and were treated with pheno-
barbital.’’9 This same child is noted as having seizures in
another 2014 publication that specifically diagramed
PRICKLE2 in the deletion.10 Thus, there are reports of
PRICKLE2 deletions in children with epilepsy in other
publications.
Sandford et al. also point out that one of the originally
described PRICKLE2 variants (c.1813G>T [p.Val605Phe]
[GenBank: NM_198859.3]) is seen in 2 of over 60,000 indi-
viduals represented in the ExAC Browser, but this certainly
does not definitively explain the functional role of any
allele. The ExAC Browser includes individuals with neuro-
developmental disorders; moreover, with a minor allele
frequency of 1.65 3 105, the allele is quite rare. In addi-
tion, this same PRICKLE2 missense variant (but no other
disease-implicated variants) was described upon exome
sequencing of a 2-year-old with multiple medical issues,
including developmental regression and episodes concern-
ing seizures.4
Sandford et al. further claim that the functional tests in
Tao et al.2 are ‘‘not consistent,’’ even though they showed
seizure susceptibility in humans, mice, and fruit flies with
mutations in PRICKLE2 orthologs. Functional biology has
many variables and can have a wide range of results. Never-
theless, the finding of more than one rare mutation in a, 2016
given individual points to the urgent need to perform
functional, personalized, precision-medicine experiments
in the age of MPS. Newly described variants must be func-
tionally validated, as rigorously as possible, in an effort to
make definitive diagnoses and find new treatments. In the
case of PRICKLE2, we already published electrophysiolog-
ical data relevant to specific subject variants in animal
and neuronal cell models,11 and we and others are now
poised to use gene editing (using CRISPR/Cas9 in subject-
derived immunocompetent stem cells) to correct individ-
ual variants and assess their pathogenecity.12
In conclusion, our original paper2 and a brief literature
review implicate PRICKLE2 mutations in epilepsy. We
propose that the letter (from Dr. Bird and colleagues) in
response to our original 2011 manuscript (from Dr. Bird
and us) entitled ‘‘Mutations in Prickle Orthologs Cause
Seizures in Flies, Mice, and Humans’’ could be a few-sen-
tence corrigendum better titled ‘‘One Family with a Rare
PRICKLE2 Mutation, Epilepsy, and a Brain Disorder Also
Has POLG Mutations that in Retrospect Explain Their
Extreme Phenotype.’’
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